ADHD
Alcobra axes ADHD drug after Phase 3 failure
January 18, 2017Research and Development ADHD, Alcobra, metadoxine
Israeli-based firm Alcobra is to pull the plug on its experimental attention deficit hyperactivity disorder (ADHD) drug metadoxine after it …
Shire says trial drug for ADHD shows positive results
June 30, 2016Research and Development, Sales and Marketing ADHD, Shire, US FDA, drug trial, regulation
UK drugmaker Shire plc (LSE: SHP) said its trial drug to treat Attention-Deficit/Hyperactivity Disorder (ADHD) showed positive topline results. Philip …
Shire launches long-acting ADHD drug in UK
March 9, 2016Sales and Marketing ADHD, Shire
Shire has launched its long-acting ADHD drug Intuniv (guanfacine) in the UK, for children and adolescents aged 6-17. The treatment …
Digital software shows benefit in ADHD trial
October 30, 2015Medical Communications ADHD, Akili, PureTech Health, attention deficit hyperactivity disorder, digital tech
A pilot study of a digital health technology designed to improve symptoms of attention deficit hyperactivity disorder (ADHD) in children …
Shire ADHD treatment Intuniv gets EU approval
September 21, 2015Sales and Marketing ADHD, Shire, attention deficit hyperactivity disorder, intuniv
The European Commission has granted marketing authorisation for Shire’s Intuniv for the treatment of ADHD in children. Intuniv (guanfacine hydrochloride prolonged …
Shire plots new ADHD drug approval
April 7, 2015Sales and Marketing ADHD, FDA, SHP465, Shire, Vyvanse, clinical trials, paediatrics
Shire is launching a new clinical trial as part of its FDA submission for a potential ADHD treatment. The company …
Shire delivers record revenues
February 16, 2015Sales and Marketing ADHD, AbbVie, Shire, Viropharma, Vyvanse, intuniv, lialda
Shire has posted strong growth in its full-year results, showing that the company is faring well even after the collapse …
Shire drug approved for binge eating disorder
February 2, 2015Sales and Marketing ADHD, FDA, Shire, Vyvanse, binge, eating, lisdexamfetamine dimesylate, obesity
Shire has become the first company to gain FDA approval for a treatment for binge eating disorder (BED) in adults …
AbbVie a step closer to Shire takeover
July 14, 2014Sales and Marketing ADHD, AbbVie, Abbott, Humira, Shire, hep C, takeover
Shire is recommending a new offer from suitor AbbVie that could finally see the US giant merge with the Dublin-based …
AbbVie spells out Shire benefits
June 26, 2014Sales and Marketing ADHD, AbbVie, Abbott, Humira, Shire, merger
AbbVie has spelt out exactly why it believes that Shire should accept its $46.5 billion bid. The US firm wants …
FDA given $20 million for generic testing
February 24, 2014Manufacturing and Production, Sales and Marketing ADHD, FDA, generics, hamburg
The FDA has been given $20 million to help it assess generic treatments, a group of drugs that makes up …
Shire ADHD drug for UK
February 14, 2013Sales and Marketing ADHD, Shire, Vyvanse, elvanse
Shire’s attention-deficit hyperactivity disorder (ADHD) drug Elvanse has been given the go-ahead for use in the UK. Elvanse (lisdexamfetamine dimesylate), …
Shire pays Impax $48 million
February 12, 2013Sales and Marketing ADHD, Adderall, Impax, Shire
Shire has paid $48 million to settle a long-running legal spat with Impax Laboratories over Shire’s supply of an authorised …
Pfizer buys NextWave Pharmaceuticals
October 23, 2012Sales and Marketing ADHD, Pfizer, Qullivant, nextwave
Pfizer is to acquire NextWave Pharmaceuticals by the end of the year in a deal that could be worth $680 …
